Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
According to Clarivate epidemiology, more than 30 million people in the United States experience migraines. Migraine prophylaxis, despite being underused, is a core treatment approach to reduce the…
Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the…
Treatment of chronic spontaneous and chronic inducible urticaria is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and off-label (e.g., DMARDs,…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…
With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…
With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key non-small-cell lung cancer patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of SCCHN for each…
Clarivate Epidemiology'’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…